Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator Drugs are an essential medication for the treatment of respiratory diseases. In Croatia, the Bronchodilator Drugs market is exhibiting a steady growth rate.
Customer preferences: The demand for Bronchodilator Drugs is primarily driven by the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The aging population and increasing air pollution are also contributing factors to the growth of the market. Patients prefer using inhalers as they provide quick relief and have fewer side effects compared to oral medication.
Trends in the market: The Bronchodilator Drugs market in Croatia is experiencing a shift towards combination therapy. Combination therapy involves the use of two or more drugs to manage respiratory diseases. This trend is driven by the need for better disease management and improved patient outcomes. The market is also witnessing an increase in the adoption of biologics for the treatment of severe asthma. Biologics are targeted therapies that work by blocking specific proteins responsible for inflammation in the airways.
Local special circumstances: Croatia has a high prevalence of smoking, which is a significant risk factor for respiratory diseases. The government has implemented several measures to reduce smoking, including a ban on smoking in public places and the introduction of graphic warning labels on cigarette packs. The increasing awareness of the harmful effects of smoking is expected to drive the demand for Bronchodilator Drugs in the country.
Underlying macroeconomic factors: The healthcare sector in Croatia is undergoing significant reforms to improve the quality of care and increase access to healthcare services. The government has introduced several policies to reduce the cost of medication, including the introduction of a reference pricing system for drugs. The reference pricing system sets a maximum price for a group of drugs with similar therapeutic effects, which has led to a decrease in the price of Bronchodilator Drugs. The increasing affordability of medication is expected to drive the demand for Bronchodilator Drugs in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
